For example, in only one-third ofthe studies, the new investigational molecules were screened againstACE, despite its well-documented relevance to cardiovascular disordersand the risk of angioedema.38 The samecould be true for neprilysin (NEP), which was included in about 10%of the screens that we studied but is not a part of the Bowes-44 orsimilar panels recommended by pharmaceutical companies. Here, MME is linked to angioedema.